The Baruch S. Blumberg Institute has received a generous gift from Distinguished Professor Richard G. Pestell, AO., MD, PhD FACP, FRACP, MBA.
Dr. Pestell assigned the Blumberg Institute an equity position in his company StromaGenesis, which is valued at $88 million, two years ago and recently increased that equity position. He previously made another equity-based gift for another of his startup companies. Dr. Pestell previously assigned an equity position in his company ProstaGene shortly before its sale in 2018, which benefited research programs at the Blumberg Institute. These forward-thinking acts of philanthropy support the Institute’s mission and demonstrate Dr. Pestell’s passion for the Institute’s scientific research and drug development work.
Louis P. Kassa III, MPA, CEO of the Blumberg Institute, Hepatitis B Foundation and Pennsylvania Biotechnology Center (PABC), said: “We are grateful to Dr. Pestell for his continued support of our mission. A gift of an equity position in a company such as StromaGenesis is a valuable asset that has the potential to help us significantly.”
Blumberg President Ju-Tao Guo, MD, said: “On behalf of the Blumberg Institute, I would like to thank Dr. Pestell for his generosity. He is clearly committed to excellence and advancing our work as a leading research institute.”
Known best for his discoveries on cell-cycle and cyclins, Dr. Pestell’s IND-enabling studies led to the development of cyclin dependent kinase inhibitors, that are now used widely for types of breast cancer. His laboratory pioneered the targeting of CCR5 for cancer therapy, currently in clinical trials. He is currently ranked #1 by Google scholar for his field of cell-cycle.
For his landmark research discoveries over the last 40 years, Dr. Pestell has received numerous awards, including election to the American Society of Clinical Investigators and the National Academies of Europe and Hungary. He received the Order of Australia from Queen Elizabeth II in 2019 for distinguished service to medicine.
Dr. Pestell is a medical oncologist who led two NCI cancer centers (Georgetown’s Lombardi Comprehensive Cancer Center, and the Sidney Kimmel Comprehensive Cancer Center), served as the Executive Vice President of Thomas Jefferson University and founded five biotechnology companies in cancer treatment and diagnostics. You can read more here.
The Baruch S. Blumberg Institute has received a generous gift from Distinguished Professor Richard G. Pestell, AO., MD, PhD FACP, FRACP, MBA.
Dr. Pestell assigned the Blumberg Institute an equity position in his company StromaGenesis, which is valued at $88 million, two years ago and recently increased that equity position. He previously made another equity-based gift for another of his startup companies. Dr. Pestell previously assigned an equity position in his company ProstaGene shortly before its sale in 2018, which benefited research programs at the Blumberg Institute. These forward-thinking acts of philanthropy support the Institute’s mission and demonstrate Dr. Pestell’s passion for the Institute’s scientific research and drug development work.
Louis P. Kassa III, MPA, CEO of the Blumberg Institute, Hepatitis B Foundation and Pennsylvania Biotechnology Center (PABC), said: “We are grateful to Dr. Pestell for his continued support of our mission. A gift of an equity position in a company such as StromaGenesis is a valuable asset that has the potential to help us significantly.”
Blumberg President Ju-Tao Guo, MD, said: “On behalf of the Blumberg Institute, I would like to thank Dr. Pestell for his generosity. He is clearly committed to excellence and advancing our work as a leading research institute.”
Known best for his discoveries on cell-cycle and cyclins, Dr. Pestell’s IND-enabling studies led to the development of cyclin dependent kinase inhibitors, that are now used widely for types of breast cancer. His laboratory pioneered the targeting of CCR5 for cancer therapy, currently in clinical trials. He is currently ranked #1 by Google scholar for his field of cell-cycle.
For his landmark research discoveries over the last 40 years, Dr. Pestell has received numerous awards, including election to the American Society of Clinical Investigators and the National Academies of Europe and Hungary. He received the Order of Australia from Queen Elizabeth II in 2019 for distinguished service to medicine.
Dr. Pestell is a medical oncologist who led two NCI cancer centers (Georgetown’s Lombardi Comprehensive Cancer Center, and the Sidney Kimmel Comprehensive Cancer Center), served as the Executive Vice President of Thomas Jefferson University and founded five biotechnology companies in cancer treatment and diagnostics. You can read more here.